| BACKGROUND
Breast cancer is estimated to be the most common invasive cancer and the leading cause of cancer deaths among women worldwide comprising 25% of all new cases and 15% of cancer-related mortality in 2012 (Ferlay et al., 2015) . There have been significant and ongoing improvements in survival, commonly attributed to the impact of earlier diagnosis through screening mammography and improved treatments (Youlden et al., 2012) .
However, these benefits have not been experienced evenly across all population groups with consistently poorer survival for rural, remote and socioeconomically disadvantaged women (Aarts, Voogd, Duijm, Coebergh, & Louwman, 2011; AIHW, 2012a, b; Singh, Williams, Siahpush, & Mulhollen, 2011) and among Indigenous/ethnic minority groups (Dachs et al., 2008; DeSantis, Ma, Bryan, & Jemal, 2014; Javid et al., 2014; Lawrenson et al., 2016; Nishri, Sheppard, Withrow, & Marrett, 2015) .
Breast cancer is also the most common cancer type recorded by cancer registries among Australian women and their second most common cause of cancer death . Although Australian female breast cancer survival rates are high compared to international benchmarks (Coleman et al., 2011) , significant variations exist including poorer survival for rural and socioeconomically disadvantaged women (AIHW, 2012a, b) . Moreover, Indigenous women, representing an estimated 3% of the total Australian population (ABS, 2013) , have significantly poorer survival than non-Indigenous women (Cancer Australia, 2012; Zhang, Condon, Dempsey, & Garling, 2014) .
Their female breast cancer incidence rates are, however, lower (AIHW, 2012a; Zhang, Condon, Rumbold, Cunningham, & Roder, 2011) .
Inequalities also exist in other Indigenous populations. For example, Indigenous women from Canada (Nishri et al., 2015) and the United States (DeSantis et al., 2014; Javid et al., 2014) have poorer survival while having lower incidence rates than their non-Indigenous counterparts while Maori women have poorer survival (and higher incidence rates) than non-Maori women in New Zealand (Lawrenson et al., 2016) . International studies have also consistently reported variations along the breast cancer continuum of care (such as screening, diagnosis and treatment) between Indigenous and non-Indigenous women (Javid et al., 2014; Kolahdooz et al., 2014; Lawrenson et al., 2016; Seneviratne et al., 2014; Tranberg et al., 2015) .
The survival inequalities among Indigenous Australians could be explained to some extent by their lower participation in the national breast cancer screening programme (38% compared to 54% for nonIndigenous women) resulting in a more advanced stage at diagnosis (AIHW, 2014c) . Where Indigenous women live is also a likely factor contributing to their poorer survival (ABS, 2013; AIHW, 2015) . While most Indigenous people live in major cities, they comprise a higher proportion of the total population within remote (16%) and very remote (50%) geographical areas (ABS, 2013; AIHW, 2015) which are also more likely to be socioeconomically disadvantaged (AIHW, 2007) .
Even though Australia has a publicly funded universal access health care system, its sheer geographical size and concentration of oncology services in major metropolitan centres (Underhill et al., 2009 ) means that a cancer diagnosis can present unique challenges for rural women including long travel distances and inadequate access to specialised care (AIHW, 2012a; Smith, 2012) . The establishment of regional cancer centres over recent years and other local-level initiatives may help improve accessibility of cancer care in the long term for rural and Indigenous cancer patients (Murphy et al., 2015; Smith, 2012) . However, additional logistic and cultural barriers, including perceptions about cancer detection and treatment and a lack of culturally appropriate care are also likely to impact on Indigenous people's utilisation of cancer care and treatment services (Cunningham, Rumbold, Zhang, & Condon, 2008; Kolahdooz et al., 2014; Miller et al., 2010; Tranberg et al., 2015) .
A clearer understanding of the underlying causes for the variations in outcomes between Indigenous and non-Indigenous women is a prerequisite to implementing effective strategies for ensuring equitable outcomes for all Australians. The focus of this systematic review was to examine and summarise existing evidence as well as identify factors that influence variations by Indigenous status along multiple phases of the breast cancer continuum of care ranging from diagnosis to treatment and survival for Australian female breast cancer patients.
It was conducted as part of a larger systematic review on variations by geographical location which also included psychosocial outcomes . The review is intended to help to identify gaps in knowledge, prioritise research strategies and inform the development of innovative evidence-based interventions to reduce inequalities in breast cancer outcomes.
| METHODS

| Terminology
The term "Indigenous" has been respectfully used throughout the review to refer to Aboriginal and Torres Strait Islander women. We acknowledge that Indigenous Australians do not represent only one group, they comprise many diverse groups, each with their own distinct culture. The recording of Indigenous status within Australian health records and administrative data sets is based on self-reported data, that is an individual identifying themselves as being either Aboriginal only, Torres Strait Islander only or both Aboriginal and Torres Strait Islander. Self-identification in response to a standard (although noncompulsory) Indigenous status question has been recognised as the most accurate way of establishing an individual's Indigenous or nonIndigenous status (AIHW, 2010) . However, the quality of Indigenous status data across various health data sets including cancer can vary widely reflecting a range of issues such as misclassification, high proportions of records with "not stated" status and inconsistencies in the collection of Indigenous status across jurisdictions (AIHW, 2013; Zhang et al., 2011) .
Due to the heterogeneity of definitions used in the existing literature to identify geographical areas, terms such as remote, rural, regional and non-metropolitan all specify locations outside Australian major cities. Hence, for the purposes of this review we collapsed geographical remoteness into metropolitan areas (typically referred to in the literature as "major cities" or "urban") and non-metropolitan areas (comprising the remaining locations).
| Clinical questions
The review was conducted according to the published PRISMA guidelines for systematic reviews (Liberati et al., 2009) . Clinical questions to guide the review were developed and finalised in consultation with a Project Steering Group including clinicians, researchers, allied health practitioners, consumer advocates and health policy representatives before beginning the review process. The questions complied with PICO guidelines (Liberati et al., 2009) that the target population (P), intervention/exposure (I), comparator (C) and outcomes (O) be clearly stated and serve to guide the review process, with the only optional element being the comparator (University of the Sunshine Coast, 2015).
The review addressed eleven clinical questions assessing variations between Indigenous and non-Indigenous women with breast cancer that were grouped into three key themes: (i) survival outcomes (one question), (ii) patient/tumour characteristics (two questions) and (iii) diagnostic and treatment outcomes (eight questions; Table 1 ).
| Literature search
Systematic searches were undertaken using PubMed, EMBASE, CINAHL and Informit databases and covered all indexed articles from 1 January 1990 to 1 March 2015. Final searches were carried out by 6 March 2015. Additional sources were the Web of Science database for cited reference searches and the Australian HealthInfoNet bibliographic database. Separate search queries (Appendix S1) were designed for each clinical question based on keywords and subject headings that reflected the review aim. The key terms of "Australia", "breast neoplasms" and "female" were coupled with Indigenous population search terms of "Indigenous", "Torres Strait Islander", "Aboriginal" and outcome terms that covered the breast cancer pathway encompassing "survival", "stage", "diagnosis age", "socioeconomic", "screening mammography", "screening rate", "re-screening", "clinical management", "patterns of care", "mastectomy", "breast reconstruction", "breast conserving", "radiotherapy", "lymph node" and "guideline adherence".
Other synonyms reflecting each of the key terms were also included.
| Inclusion criteria
Studies were eligible if they met the following inclusion criteria: (i) population comprised adult including Indigenous women with breast cancer (ii) the setting was Australia; (iii) the outcome measure was survival, patient or tumour characteristics, screening participation or frequency, clinical management, patterns of initial care or post-treatment follow-up; and (iv) either quantitative statistics were presented on Indigenous versus non-Indigenous comparisons or there was a qualitative analysis by Indigenous status.
Only English language peer-reviewed original research articles were considered. Reviews, editorials, books, conference abstracts and commentaries were excluded, although their reference lists were searched for other relevant articles.
| Review process
After removing duplicates, the titles and abstracts of all articles retrieved by the literature search were independently reviewed by two authors (first PD, second PY, DY, PB or JA) to assess their relevance to the specified clinical question. Discrepancies were resolved through discussion between the two reviewers and, if necessary, the other reviewers. Full text versions of all potentially relevant articles were then obtained for more detailed independent evaluation by two reviewers as before. Articles were classified as "include" or "exclude" with reasons for exclusion being documented. Reviewer decisions were compared and any disagreements resolved by consensus.
| Critical appraisal
The methodological quality of each included article was assessed independently by two reviewers as described previously . Studies were assessed on six items based on the Newcastle-Ottawa Scale (NOS; Wells et al., 2013 9. In women diagnosed with breast cancer, do Indigenous women experience fewer treatment options compared to non-Indigenous women in Australia?
10. In women diagnosed with breast cancer, are Indigenous women less likely to complete prescribed treatment compared to non-Indigenous women in Australia?
11. In women diagnosed with breast cancer, are Indigenous women less likely to participate in recommended follow-up compared to non-Indigenous women in Australia? each of the nine assessed criteria (Appendix S2) using an ordinal scale to rate the risk of bias: 0 (high), 1 (intermediate) and 2 (low). A total score was obtained from the sum of the nine individual scores.
Instances of marked inconsistencies in the total scores between the two reviewers for individual articles were resolved by consensus.
Finally, each article was assigned to categories defined as "high" (14-18), "moderate" (9-13.5) or "low" (<9) quality based on the summary score (average of the total scores from the two reviewers; Youl et al., 2016) . All included articles provided sufficient information to assess bias and none were excluded due to their quality score. 
| Data extraction
One reviewer recorded relevant study characteristics including citation, design, source, sample size including number of Indigenous women (where stated), statistical methods, outcome(s) and key findings in a customised database. These data were subsequently verified by another reviewer and any errors or discrepancies resolved after consulting the original source.
| RESULTS
| Study selection
The steps in the review process are shown in a PRISMA flow diagram Excluded studies with reasons for exclusion are listed in Appendix S3.
| Study characteristics
All of the 16 included articles were quantitative and 15 used administrative data sources (population-based cancer registries and/or screening databases) and one was based on data collected through a single-hospital clinical audit. The majority (14) were state-based with only two assessing national data. In terms of study quality, the average score was 14.0 (range: 6.5-17) with 12 (75%) of the included studies based on a reliable and objective data source (cancer registries) that contributed to higher quality.
Thirteen of the included studies adjusted for age while around half also adjusted for the year of diagnosis and various socio-demographic factors. However, the limited ability of cancer registry-based studies to adjust for treatment and clinical variables in statistical analysis reduced their quality scores (insofar as the effects of these factors on survival could not be explored). Other limitations included lack of follow-up in some studies.
Twelve of included studies were rated as high quality, three as moderate and one as low quality. No study provided Level I evidence, while ten provided Level II evidence, five Level III-3 and one Level-IV evidence ( Table 2 ).
The largest study involved 36,204 Indigenous women from a screening database and approximately 450 who were diagnosed with breast cancer following screening (Roder, Webster, Zorbas, & Sinclair, 2012 ) while another included 6,053 Indigenous women who had been screened for breast cancer (Sim et al., 2012) The number of Indigenous women in the remaining 14 study cohorts was smaller and ranged from 44 to 420. In terms of overall percentages, Indigenous women comprised around 1% or less of the overall cohort for ten out of 14 studies (where this could be calculated), 3%-5% (two studies), and around 12% in the two remaining studies.
| Key findings
Studies were summarised for individual clinical questions by the three main themes: (i) survival outcomes, (ii) patient/tumour characteristics and (iii) diagnostic and treatment outcomes. Several studies assessed multiple outcomes. Due to the variability across studies in terms of their quality, levels of evidence, time period, design, proportions of Indigenous women involved and analytical methods we have purposefully interpreted any general patterns with caution.
| Survival outcomes
There was a consistent and universal pattern of poorer survival for Indigenous women than non-Indigenous women diagnosed with breast cancer across all nine (eight high and one moderate quality) included studies both nationally Roder et al., 2012) and at the state level (Chong & Roder, 2010 Table 3 ). Indigenous women had a 6%-15% (absolute) lower 5-year unadjusted survival [from breast cancer or any cause] than non-Indigenous women (Chong & Roder, 2010; Condon et al., 2005b Condon et al., , 2014 Dasgupta et al., 2012; Morrell et al., 2012; Roder et al., 2012; Spilsbury et al., 2005; Supramaniam et al., 2014) .
All of the seven high-quality studies (Condon et al., 2005b Dasgupta et al., 2012; Morrell et al., 2012; Roder et al., 2012; Spilsbury et al., 2005; Supramaniam et al., 2014 ) that also reported survival estimates after adjustment for survival determinants including socio-demographics, spread of disease, comorbidities or treatmentrelated factors found poorer adjusted survival among Indigenous women, although only five reached statistical significance (Condon et al., 2005b Dasgupta et al., 2012; Morrell et al., 2012; Roder et al., 2012) .
The adjusted estimates differed by the combination of covariates considered during statistical analysis. None of the four papers that reported significant survival differentials after adjusting for a measure of stage at diagnosis considered comorbidities or treatment-related factors (Condon et al., 2005b; Dasgupta et al., 2012; Morrell et al., 2012; Roder et al., 2012) .
The number of Indigenous women ranged from 44 (Condon et al., 2005b) to 446 (Roder et al., 2012) for the five studies that reported significant adjusted survival differentials, comprising 12% of the cohort in one (Condon et al., 2005b) , and 1% in three Dasgupta et al., 2012; Roder et al., 2012) , while it could not be calculated for the remaining study (Morrell et al., 2012) . Indigenous women also comprised 1% of the study cohort (n = 87 and 288 respectively)
for the two studies where adjusted survival estimates were not statistically significant (Spilsbury et al., 2005; Supramaniam et al., 2014) .
While these relatively small numbers may have impacted the power to detect statistically significant differences in these studies, this was not an issue for the three small studies (n < 346) that did identify significant differences.
| Patient and tumour characteristics
| Patient characteristics
Both of the included high-quality studies reported differences in patient characteristics by Indigenous status (Table 4) . Nationally, a study of 63,733 women (1% Indigenous) found that Indigenous female breast cancer patients were diagnosed at a younger age and were significantly more likely to reside in socioeconomically disadvantaged or geographically remote areas (Roder et al., 2012) with similar patterns reported by a state-level study (Supramaniam et al., 2014) . Indigenous women with breast cancer also had a greater comorbidity burden than their non-Indigenous counterparts (Supramaniam et al., 2014) .
| Tumour characteristics
A consistent pattern of more advanced disease at diagnosis among Indigenous women was evident across four (all high quality) of the five included studies (Table 4) . A large national study (n = 63,773, 1%
Indigenous) reported that Indigenous women were diagnosed with a higher proportion of larger sized (>15 mm) and node-positive tumours (Roder et al., 2012 ) while two state-based studies (n = 359, 12%
Indigenous and n = 27,850, 1% Indigenous) found that they were more likely to present with advanced (including both regional and distant) disease (Condon et al., 2005b; Supramaniam et al., 2014) . Another study indicated that although Indigenous women had a higher likelihood of being diagnosed with advanced disease, the adjusted effect was not significant; however, statistical significance was achieved in sensitivity analyses when women with unknown spread of disease were excluded (Gibberd, Supramaniam, Dillon, Armstrong, & O'Connell, 2015) . Finally, a moderate quality single-hospital-based clinical audit reported that while on average Indigenous women presented with slightly larger tumours (32 mm versus 23 mm), this difference was not statistically significant, possibly reflecting the small (n = 161, only 18 Indigenous) sample size (Shaw & Elston, 2003) , although Indigenous women were more likely to show nodal involvement. We found no published study that assessed the differences in breast cancer tumour biology such as grade or hormonereceptor status by Indigenous status among Australian women.
| Diagnostic and treatment outcomes
The following section summarises studies examining variations by Indigenous status in breast cancer screening (Table 5) and treatment ( Adjusted for age and year at diagnosis and interaction terms of Indigenous status with each of these two terms.
e Adjusted for age at diagnosis, socio-demographic factors, spread of disease, residential remoteness and area-disadvantage.
f Adjusted for age at diagnosis, year at diagnosis and spread of disease.
g Adjusted for age at diagnosis, diagnostic period, residential remoteness, area-disadvantage, tumour size, nodal spread and time from last screening mammography to diagnosis.
h Adjusted for age at diagnosis, diagnostic period, comorbidities, residential remoteness, area-disadvantage, hospital type and treatment-related factors.
i Adjusted for age and year at diagnosis, comorbidities, spread of disease, residential remoteness, area-disadvantage and surgical procedure. 
T A B L E 3 (Continued) T A B L E 4 Characteristics of included studies on patient and tumour characteristics by Indigenous status
| Screening rate
Both included studies found that Indigenous women had lower participation rates (defined as having at least one screening mammogram in a 2-year period; AIHW, 2014b) for mammographic screening through the BreastScreen Australia program. Nationally, Indigenous women were 27% less likely to participate in breast screening in a high-quality study comprising in excess of 5.4 million women (1% Indigenous; Roder et al., 2012) . A low-quality state-based study (McLean & Condon, 1999 ) also suggested that Indigenous women presented for mammograms through the BreastScreen program at half the rate of non-Indigenous women, although the actual rates were not stated.
| Rescreening rates
Two (both high quality) of three included studies reported lower rescreening rates (defined as having another screening mammogram through BreastScreen Australia within 2 years of the initial screen)
for Indigenous women. A large national study of 5.4 million women (1% Indigenous) found that Indigenous women were 40% less likely to be rescreened than non-Indigenous women (Roder et al., 2012) , while at the state-level Indigenous women were twice as likely to not attend for rescreening in another study (O'Byrne, Kavanagh, Ugoni, & Diver, 2000) . However, in a single moderate quality study (Sim et al., 2012) , there were no statistically significant differences in rescreening rates for 6,053 Indigenous women when comparing initial falsepositive and true-negative mammograms, whereas women overall (n = 582,729) were less likely to return for rescreening following a false-positive result.
| Clinical management
Results were inconsistent across the five included studies, and depended on the time period of data collection. While three (two high, one moderate quality) earlier state-level studies (n = 161-11,024 women, 1%-12% Indigenous) found no evidence for variation in clinical management between Indigenous and non-Indigenous women (Hall & Holman, 2003; Hall et al., 2004; Shaw & Elston, 2003) , two high-quality studies published after 2010 showed a consistent pattern of variations in clinical management, both nationally for 5.4 million women (1% Indigenous; Roder et al., 2012 ) and at a state-level (n = 27,833, 1% Indigenous; Supramaniam et al., 2014) . In particular, Indigenous women were 40% less likely to receive any surgery (Supramaniam et al., 2014) , and where surgical management was undertaken, they were more likely to undergo mastectomy rather than complete local excision compared to non-Indigenous women (Roder et al., 2012; Supramaniam et al., 2014 ).
| Recommended clinical management
Of two included studies, one high-quality state-level study (n = 27,833, 1% Indigenous) reported that Indigenous women were 40% less likely to undergo any surgery for breast cancer within Classified as localised (node-negative confined to breast tissue) and advanced (includes regional or distant disease).
d
Classified as localised (node-negative confined to breast tissue), regional (involves regional lymph nodes or adjacent tissues, includes locally advanced disease) or distant (spread to distant organs or lymph nodes, includes metastatic disease).
e Adjusted for age and year at diagnosis, residential remoteness and area-disadvantage.
T A B L E 4 (Continued)
T A B L E Screening participation is defined as having had at least one screening mammography through BreastScreen Australia over a 2-year period; rescreening is having returned for another screening mammography within recommended interval of 2 years from the initial screening.
c Screening interval of 27 months used of recommended 24 months to allow for potential delays in screening availability and data transfer.
Adjusted for age, residential remoteness, area-disadvantage, screening time period and screening round.
e Adjusted for age, language spoken at home, residential remoteness, area-disadvantage, hormone replacement therapy, family breast cancer history and characteristics related to initial screening (recruitment method, type of service attended, symptoms and assessment status).
T A B L E 6 Characteristics of included studies on treatment outcomes by Indigenous status 12 months of diagnosis after adjustment for a range of key demographic and clinical factors (Supramaniam et al., 2014) . A small (n = 161, 12% Indigenous) moderate quality single-hospital-based clinical audit reported that 40% of Indigenous women with breast cancer had chemotherapy and 73% underwent radiotherapy compared to 48% and 65% of non-Indigenous women respectively (Shaw & Elston, 2003) . However, there was no mention of clinical indicators (such as spread of disease) or surgical type, hence it was unclear whether these treatments followed recommended guidelines.
No articles met the inclusion criteria for variations by Indigenous status in relation to referral patterns, treatment completion or posttreatment follow-up according to current national guidelines (NBOCC, 2010) . Nor were there any studies on differences in specific treatment choices presented to Indigenous and non-Indigenous female breast cancer patients in Australia. (Chong & Roder, 2010; Condon et al., 2014; Morrell et al., 2012; Roder et al., 2012; Supramaniam et al., 2014) . However, since none of the included studies specifically looked at variations in uptake of surgery or type of surgery by tumour characteristics such as stage or by decision-making processes, it is not possible to make conclusions about these factors. The social determinants of health including lower educational levels, poverty, cultural marginalisation, racism, poor housing and residing in more geographically remote areas are also likely contributors to the observed inequalities (AIHW, 2012a, b; Azzopardi, Walsh, Chong, & Taylor, 2014; Baade, Dasgupta, Youl, Pyke, & Aitken, 2016; Cramb, Mengersen, Turrell, & Baade, 2012; Dasgupta et al., 2012) . Moreover, barriers such as a lack of awareness and knowledge of breast cancer symptoms, benefits of earlier detection and/or treatments and the limiting impact of chronic disease on treatment options, especially multimodal therapies for breast cancers, have all been identified as influencing the poorer prognostic outcomes for Indigenous cancer patients (Bernardes, Whop, Garvey, & Valery, 2012; Cunningham et al., 2008; Kolahdooz et al., 2014; Miller et al., 2010; Tranberg et al., 2015; Valery, Coory, Stirling, & Green, 2006) .
| DISCUSSION
Furthermore, although evidence was limited, the consistent pattern of lower participation in breast cancer screening for Indigenous women may explain to some extent their higher likelihood of presenting with more advanced disease. Hence, the development and implementation of effective strategies to reduce barriers and promote timely screening through the existing and well established populationbased national mammographic program (BreastScreen) in Australia is likely to improve detection of breast cancer at earlier stages and improve morbidity and potentially survival outcomes for diverse and under-screened populations. Such initiatives must, however, be culturally appropriate (Kolahdooz et al., 2014; Miller et al., 2010) , involve community engagement in programme design and implementation and be designed to be informative about the benefits of mammographic screening.
More advanced stage at diagnosis is arguably the most important factor leading to poorer survival among Indigenous women diagnosed with breast cancer, likely due to issues such as delays in presentation and diagnosis. Potential reasons for these delays likely include factors relating to timely access to appropriate health care and patientrelated factors such as fear and cultural beliefs, as well as interactions between them (Javid et al., 2014; Kolahdooz et al., 2014; Roder et al., 2012; Whop et al., 2012) . Barriers to timely diagnosis among Indigenous cancer patients need to be identified to guide the implementation of evidence-based interventions if disparities in outcomes are to be minimised.
The review found that Indigenous women with breast cancer were less likely to receive any surgery than their non-Indigenous counterparts and that when surgical management was undertaken there were variations in uptake of different procedures by Indigenous status.
Given that women diagnosed with breast cancer in remote areas are more likely to be Indigenous (Roder et al., 2012; Supramaniam et al., 2014) , consistent with the underlying population distribution, possible causes for the observed variations in patterns of care are likely to include more limited access to specialised oncological services and multidisciplinary care.
Although recent initiatives such as the establishment of Regional Cancer Centres (Murphy et al., 2015; Smith, 2012) should increase access to specialised services in regional Australia, geographical variations in access to multidisciplinary care remains a challenge. A multidisciplinary team approach to treatment planning is regarded as best practice and has been consistently shown to improve clinical outcomes for cancer patients (Prades, Remue, van Hoof, & Borras, 2015 (Cunningham et al., 2008; Kolahdooz et al., 2014; Miller et al., 2010; Tranberg et al., 2015) .
Hence, other innovative strategies also need to be considered and explored, such as models of care that are specifically designed to address the social, cultural and treatment needs of Indigenous cancer patients. Additional approaches include cancer education programmes which support the role of Indigenous Health Workers (Le et al., 2013; Murphy et al., 2015; Smith, 2012; Whop et al., 2012; Zorbas & Elston, 2016) , a key source of cancer information, health promotion and support for Indigenous patients undergoing cancer treatment (Bernardes et al., 2012) .
While the review found consistent evidence for variations in breast cancer survival, studies reporting other outcomes were limited. In particular, the review did not identify any articles in relation to referral patterns, treatment choices, treatment completion or post-treatment follow-up and only very limited information on receipt of adjuvant therapies and guideline concordant care for female Indigenous breast cancer patients in Australia. As such, it highlighted the need for highquality large-scale research into all aspects of patterns of breast cancer care for Indigenous women.
Studies from other countries have consistently attributed the well-documented poorer breast cancer survival (Dachs et al., 2008; DeSantis et al., 2014; Javid et al., 2014; Lawrenson et al., 2016; Nishri et al., 2015) in Indigenous populations to greater comorbidity burden, socioeconomic disadvantage, geographic location, cultural issues and variations in the timeliness, accessibility and quality of cancer services involving early detection, diagnosis and treatment (Javid et al., 2014; Kolahdooz et al., 2014; Lawrenson et al., 2016; Seneviratne et al., 2014; Tranberg et al., 2015) . For example, Maori women are more likely to be diagnosed with advanced disease and experience delays in receiving treatment than non-Maori women in New Zealand (Lawrenson et al., 2016; Seneviratne et al., 2014) while in the United States, American Indians/Alaskan Native women are less likely to receive guideline concordant care than White women (Javid et al., 2014) . The persistence of these variations among diverse Indigenous populations spanning a range of geographical settings and health care systems indicates both the likely similarities of the underlying issues and challenges involved in addressing them.
Some common themes that emerged from these studies include the need to promote awareness of and facilitate access to screening (Kolahdooz et al., 2014; Lawrenson et al., 2016; Tolma, Stoner, Li, Kim, & Engelman, 2014) , improve general health of Indigenous women (Lawrenson et al., 2016; Sheppard, Chiarelli, Marrett, Nishri, & Trudeau, 2011) as well as prioritising further investigation into factors that impact treatment, so as to guide the design of culturally appropriate programmes and services that address their needs (Javid et al., 2014; Kolahdooz et al., 2014; Lawrenson et al., 2016; Tolma et al., 2014; Tranberg et al., 2015) .
| Limitations
Considerable efforts were made to assess existing literature for each clinical question by creating complex queries to search multiple databases and using the reference lists of retrieved articles, reviews and government reports to identify other articles. However, it is still possible that the criteria used for searches could have unintentionally led to relevant articles being excluded. All included articles were restricted to those indexed in the accessed databases.
Studies were heterogeneous in terms of their data sources, methodology, quality and level of evidence, time period and geographical settings. The number of Indigenous women in the study cohorts was typically small. These issues hindered data comparability across studies and, combined with the predominance of state-based findings, made extrapolation of the individual results to form a national perspective challenging. The variability in individual study objectives also to some extent limited our ability to generalise results to a wider Indigenous population. Furthermore, the extent to which state-specific population-based results cancer can be generalised to the national setting is unknown. We also acknowledge that the emphasis was on internal validity in assessments of study quality and strength of evidence.
The establishment of a national population-based system for doc- recording Indigenous status at a high enough quality for reporting purposes (Zhang et al., 2011) . As such, strategies to facilitate implementation of existing guidelines to improve Indigenous status data, especially in the health and pathology sectors, need to be developed .
Finally, no qualitative studies met the inclusion criterion for this review. International reviews have also identified the lack of qualitative studies involving diverse Indigenous peoples (Kolahdooz et al., 2014; Tranberg et al., 2015) and the crucial need for high-quality studies to provide useful insights from the perspective of Indigenous cancer patients. Such insights would help guide the development of effective context-specific programmes to improve outcomes. These gaps likely reflect among other issues the cultural impediments in conducting qualitative studies among Indigenous population and the lack of suitable culturally sensitive standardised measures (Garvey et al., , 2015 . Finally, the review highlighted the need for high-quality research including qualitative studies and narratives along the entire breast cancer continuum of care for Indigenous women if evidence-based initiatives are to be developed to better address disparities in cancer outcomes and patients' needs.
| CONCLUSIONS
